Vaccines in the management of hypertension

Bibliography

• Chobanian AV, Bakris GL, Black HR, Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Cutler JA, Sorlie PD, Wolz M, Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27
   PubMed Web of Science ®Google Scholar
• Cherry DK, Hing E, Woodwell DA, Rechtsteiner EA. National ambulatory medical care survey: 2006 summary. Natl Health Stat Rep 2008;3:1-39
   PubMedGoogle Scholar
• Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women. Hypertension 2005;46:280-6
   PubMed Web of Science ®Google Scholar
• U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007;147:783-6
   PubMed Web of Science ®Google Scholar
• Vikrant S, Tiwari SC. Essential hypertension – pathogenesis and pathophysiology. J Indian Acad Clin Med 2001;2:140-61
   Google Scholar
• Deng AY. Genetic basis of polygenic hypertension. Hum Mol Genet 2007;16:R195-R202
   PubMed Web of Science ®Google Scholar
• Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003;21:37-42
   PubMedGoogle Scholar
• Torp-Pedersen C, Kober L, Carlsen J. Angiotensin-converting enzyme inhibition after myocardial infarction: the trandolapril cardiac evaluation study. Am Heart J 1996;132:235-43
   PubMed Web of Science ®Google Scholar
• Cohn JN. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in heart failure trial. Cardiology 1999;91(Suppl 1):19-22
   PubMedGoogle Scholar
• Shahinfar S, Dickson TZ, Ahmed T, Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney Int Suppl 2002;82:S64-S67
   PubMedGoogle Scholar
• Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 2001;12:2832-7
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Bühler FR, Bolli P, Kiowski W, Renin profiling to select antihypertensive baseline drugs. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984;77(2A):36-42
   PubMed Web of Science ®Google Scholar
• Laragh JH, Resnick LM. Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int Suppl 1988;25:S162-S174
   PubMedGoogle Scholar
• Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009;22:112-21
   PubMed Web of Science ®Google Scholar
• Goldblatt H, Haas E, Lamfrom H. Antirenin in man and animals. Trans Assoc Am Physicians 1951;64:122-5
   PubMedGoogle Scholar
• Frank MH. Renin in experimental renal hypertension in monkeys. Circ Res 1963;12:241-55
   PubMed Web of Science ®Google Scholar
• Hartroft PM. Juxtaglomerular cells. Circ Res 1963;196:525-38
   Google Scholar
• Michel JB, Guettier C, Philippe M, Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987;84:4346-50
   PubMed Web of Science ®Google Scholar
• Reade R, Michel JB, Carelli C, Immunization of spontaneously hypertensive rats against angiotensin 1. Arch Mal Coeur Vaiss 1989;82:1323-8
   PubMedGoogle Scholar
• Downham MR, Auton TR, Rosul A, Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003;56:505-12
   PubMed Web of Science ®Google Scholar
• LeClerc C, Schutze MP, Deriaud E, Przewlocki G. The in vivo elimination of CD4+ cells prevents the induction but not the expression of carrier-induced epitopic suppression. J Immunol 1990;145:1343-9
   PubMed Web of Science ®Google Scholar
• Brown MJ, Coltart J, Gunewardena K, Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004;107:167-73
   PubMed Web of Science ®Google Scholar
• Brookes L. New antihypertensive therapies and old hypertensive risks?. Medscape cardiology. Published online: 17 April 2008. Available from: http://www.medscape.com/viewarticle/572933 [Last accessed 23 April 2010].
   Google Scholar
• Johnston CI, Hutchinson JS, Mendelsohn FA. Biological significance of renin–angiotensin immunization. Circ Res 1970;26(Suppl II):215-22
   Google Scholar
• Macdonald GJ, Louis WJ, Renzini V, Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res 1970;27:197-211
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, The influence of antigen organization on B cell responsiveness. Science 1993;262:1448-51
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Tissot F, Lechner P, A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002;20:3104-12
   PubMed Web of Science ®Google Scholar
• Lechner F, Jegerlehner A, Tissot AC, Virus-like particles as a modular system for novel vaccines. Intervirology 2002;45:212-21
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Adelstein S, Basten A. The need for central and peripheral tolerance in the B cell repertoire. Science 1990;248:1373-9
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 2007;7:143-55
   PubMed Web of Science ®Google Scholar
• Ambühl PM, Tissot AC, Fulurija A, A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007;25:63-72
   PubMed Web of Science ®Google Scholar
• Tissot AC, Maurer P, Nussberger J, Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008;371:821-7
   PubMed Web of Science ®Google Scholar
• Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43
   PubMed Web of Science ®Google Scholar
• Zhu F, Liao YH, Li LD, Target organ protection from a novel angiotensin II receptor (AT-1) vaccine ATR 12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006;3:107-14
   PubMed Web of Science ®Google Scholar
• Feng Z, Yu-Hua L, Liudong L. Observation of long-term efficacy and safety of an ATR12181 vaccine against hypertension in SHR [abstract 2753]. Circulation 2006;114:II 575
   Google Scholar
• de Gasparo M, Catt KJ, Inagami T, International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72
   PubMed Web of Science ®Google Scholar
• Wallukat G, Homuth V, Fischer T, Patients with preeclampsia develop agonistic antibodies against the angiotension AT1 receptor. J Clin Invest 1999;103:945-52
   PubMed Web of Science ®Google Scholar
• Li LD, Liao YH, Zhou ZH, Effects of active immunization with agiotensin II receptor type 1 peptides on blood pressure and cardiovascular remodeling in spontaneous hypertensive rats. Zhongguo Mian Yi Xue Za Zhi 2005;21:372-6
   Google Scholar
• Slade BA, Leidel L, Vellozzi C, Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009;49:303-26
   PubMed Web of Science ®Google Scholar
• Verdier F. Non-clinical vaccine safety assessment. Toxicology 2002;174:37-43
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9
   PubMed Web of Science ®Google Scholar
• Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001;4:751-5
   Google Scholar
• Maurer P, Jennings GT, Willers J, A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005;35:2031-40
   PubMed Web of Science ®Google Scholar
• Lindblad E. Aluminium adjuvants in retrospect and prospect. Vaccine 2004;22:3658-68
   PubMed Web of Science ®Google Scholar
• Paul S, Kenny AB, Hitzig WH. Immune response to keyhole-limpet hemocyanin in the human. Int Arch Allergy Appl Immunol 1974;47:155-60
   PubMedGoogle Scholar
• LaMarca B, Parrish M, Ray LF, Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009;54:905-9
   PubMed Web of Science ®Google Scholar
• Dechend R, Müller DN, Wallukat G, AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol 2004;24:571-9
   PubMed Web of Science ®Google Scholar
• Nydegger UE. Immune complex pathophysiology. Ann NY Acad Sci 2007;1109:66-83
   PubMed Web of Science ®Google Scholar
• Janin J, Cothia C. The structure of protein-protein recognition sites. J Biol Chem 1990;265:16027-30
   PubMed Web of Science ®Google Scholar
• Van Regenmortel MHV. Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 1996;9:465-72
   PubMedGoogle Scholar
• Gilman S, Koller M, Black RS, Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
   PubMed Web of Science ®Google Scholar
• Wakerlin GE. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 1958;17:653-7
   PubMed Web of Science ®Google Scholar
• Weiser RA, Johnson AG, Hoober SW. The effect of antirenin on the blood pressure of the rat with experimental renin hypertension. Lab Invest 1969;20:326-31
   PubMed Web of Science ®Google Scholar
• Hill RW, Chester JE, Wisenbaugh PE. The effect of intravenous antirenin injection on chronic experimental and acute renin induced hypertension in dogs. Lab Invest 1970;22:404-16
   PubMed Web of Science ®Google Scholar
• Romero JC, Hoober SW, Kozak TJ, Warzymski RJ. Effect of antirenin on blood pressure of rabbits with experimental renal hypertension. Am J Physiol 1973;225:810-7
   PubMed Web of Science ®Google Scholar
• Skeggs LT, Kahn JR, Levine M, Chronic one-kidney hypertension in rabbit. Circ Res 1975;7:715-24
   Google Scholar
• Slater EE, Corvol P, Menard J, Antisera to human renin normalizes renin-dependent hypertension in the monkey: therapeutic implications. Clin Exp Hypertens 1984;A6:923-37
   Google Scholar
• Wood JM, Feusser C, Gulati N, Monoclonal antibodies against human renin: blood pressure effect in the marmoset. Hypertension 1986;8:600-5
   PubMed Web of Science ®Google Scholar
• Katz J, Skom JH, Walkerlin G. Pathogenesis of spontaneous and pyelonephritic hypertension in dog. Circ Res 1957;5:137-43
   PubMed Web of Science ®Google Scholar
• Helmer M. Studies on renin antibodies. Circulation 1958;17:648-52
   PubMed Web of Science ®Google Scholar
• Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect on experimental renal hypertension. J Exp Med 1964;139:425-35
   Google Scholar
• Michel JP, Galen FX, Guettier C, Sayah S. Immunological approach to blockade of the renin-substrate reaction. J Hypertens Suppl 1989;7(2):S63-70
   PubMedGoogle Scholar